FDMT241115C2500
- 0.00
- 0.000.00%
4D Molecular Therapeutics Newsroom
We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely
4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data
4D Molecular Therapeutics Analyst Ratings
4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating
Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82
4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate
4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital
A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)
Express News | 4D Molecular Therapeutics Inc : Leerink Partners Cuts Target Price to $36 From $40
4d Molecular Therapeutics Executive Sells $8.2k in Stock
Express News | 4D Molecular Therapeutics : Expect to Initiate 4Front-1 in Q1 2025
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40
4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital
The Latest Analyst Ratings For 4D Molecular Therapeutics
Express News | Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics
Wall Street Analysts Think 4D Molecular Therapeutics (FDMT) Could Surge 225.1%: Read This Before Placing a Bet